Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Hematologic Malignancies
Endocrinology
Questions discussed in this category
For patients with mild CKD, how do you decide between zoledronic acid and denosumab for bone protection in patients with multiple myeloma?
For pts w/ eGFR between 30-60
1 Answer available
Do you routinely offer a bisphosphonate or denosumab to multiple myeloma patients without skeletal lesions?
Recommendations in guidelines are discordant (ASCO vs NCCN vs UptoDate).
2 Answers available
11973
9822
Papers discussed in this category
Cancer,
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.
Blood, 2013-10-24
The impact of response on bone-directed therapy in patients with multiple myeloma.
The Lancet. Oncology, 2011-08
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial.
The Lancet. Oncology, 2018-03
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
Related Topics in Hematologic Malignancies
Breast Cancer
Head and Neck Cancers
Radiation Oncology
Gynecologic Cancers
Palliation
Neuro-Oncology
Gastrointestinal Cancers
Genitourinary Cancers
Pediatric Oncology
Sarcoma